Scholarlink

Abstract <p>Extracellular vesicles (EVs) have gained prominence as advanced drug delivery systems due to their inherent merits. Recent advancements highlight their utility in transporting therapeutic proteins with significant progress in targeted therapies. To optimize EV efficacy, engineering strategies focus on enhancing cargo encapsulation efficiency. The robust interaction between immunoglobulin G Fc fragments and the cytoplasmic receptor TRIM21 offers a novel framework for stable cargo loading. This study identifies Ras-related GTP-binding protein D (RRAGD) as a critical regulator of lysosomal biogenesis and function. Leveraging Fc-TRIM21 interactions, engineered EVs encapsulating RRAGD were developed. Surface modification with CAP peptides enhanced nucleus pulposus (NP) cell-targeting specificity of EVs. In vitro and in vivo experiments demonstrated that engineered EVs ameliorated lysosomal dysfunction and suppressed apoptosis in NP cells, and slowed intervertebral disc degeneration (IDD) progression. The mechanistic analysis revealed the functional co-localization of RRAGD with lysosomal marker LAMP1 and lysosomal regeneration transcription factor TFEB, indicating lysosomal targeting. This study establishes CAP-modified engineered EVs based on the Fc/TRIM21 platform as a therapeutic strategy to restore lysosomal homeostasis and counteract IDD pathogenesis, underscoring the potential of EV-based therapies for degenerative disc diseases.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Customized extracellular vesicles targeting lysosomal biogenesis deliver therapeutic cargo for intervertebral disc degeneration treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月11日

查看全文
  • Zhiwei Liao,
  • Zixuan Ou,
  • Bide Tong,
  • Shuai Li,
  • Cao Yang

摘要

Abstract

Extracellular vesicles (EVs) have gained prominence as advanced drug delivery systems due to their inherent merits. Recent advancements highlight their utility in transporting therapeutic proteins with significant progress in targeted therapies. To optimize EV efficacy, engineering strategies focus on enhancing cargo encapsulation efficiency. The robust interaction between immunoglobulin G Fc fragments and the cytoplasmic receptor TRIM21 offers a novel framework for stable cargo loading. This study identifies Ras-related GTP-binding protein D (RRAGD) as a critical regulator of lysosomal biogenesis and function. Leveraging Fc-TRIM21 interactions, engineered EVs encapsulating RRAGD were developed. Surface modification with CAP peptides enhanced nucleus pulposus (NP) cell-targeting specificity of EVs. In vitro and in vivo experiments demonstrated that engineered EVs ameliorated lysosomal dysfunction and suppressed apoptosis in NP cells, and slowed intervertebral disc degeneration (IDD) progression. The mechanistic analysis revealed the functional co-localization of RRAGD with lysosomal marker LAMP1 and lysosomal regeneration transcription factor TFEB, indicating lysosomal targeting. This study establishes CAP-modified engineered EVs based on the Fc/TRIM21 platform as a therapeutic strategy to restore lysosomal homeostasis and counteract IDD pathogenesis, underscoring the potential of EV-based therapies for degenerative disc diseases.

Graphical Abstract